Consequently, cancer therapy is constrained by the toxicity to normal cells and the emergence of drug resistance in cancer cells, highlighting an urgent need for novel anticancer compounds effective against both wild-type and T790M-positive EGFR-expressing NSCLC. Here, EGFR is linked to non-small cell lung carcinoma.